Kyle A Davis1, Daphne O Davis1. 1. Department of Pharmacy, Wake Forest Baptist Medical Center, Winston-Salem, NC, USA.
Abstract
OBJECTIVE: To evaluate the efficacy and safety of direct oral anticoagulant (DOAC) therapy in hospitalized patients with suspected heparin-induced thrombocytopenia (HIT). METHODS: Retrospective cohort study of adult patients prescribed apixaban, dabigatran, or rivaroxaban for the treatment of acute HIT from January 1, 2013 to January 1, 2017. Eligibility requirements included an intermediate or high pretest probability for HIT (4T score≥4) and a positive IgG-specific anti-PF4/heparin complex assay. The primary outcome measure was the composite of newly diagnosed venous or arterial thromboembolism, gangrene, or amputation due to critical limb ischemia during hospitalization. RESULTS: A total of 12 patients were included for analysis, five of which experienced HIT-related thrombosis prior to initiation of DOAC therapy. Seven patients received parenteral therapy with argatroban prior to initiation of DOAC treatment. Nine patients were treated with apixaban while three received rivaroxaban for an average of 9.33 days while hospitalized. Zero patients experienced the primary outcome of HIT-related thrombosis, and no patients experienced major bleeding post DOAC initiation. All patients achieved platelet recovery while receiving DOAC therapy. CONCLUSIONS: In this small retrospective study of adult patients treated for acute HIT, treatment with DOAC therapy was not associated with in-hospital thrombotic or hemorrhagic events.
OBJECTIVE: To evaluate the efficacy and safety of direct oral anticoagulant (DOAC) therapy in hospitalized patients with suspected heparin-induced thrombocytopenia (HIT). METHODS: Retrospective cohort study of adult patients prescribed apixaban, dabigatran, or rivaroxaban for the treatment of acute HIT from January 1, 2013 to January 1, 2017. Eligibility requirements included an intermediate or high pretest probability for HIT (4T score≥4) and a positive IgG-specific anti-PF4/heparin complex assay. The primary outcome measure was the composite of newly diagnosed venous or arterial thromboembolism, gangrene, or amputation due to critical limb ischemia during hospitalization. RESULTS: A total of 12 patients were included for analysis, five of which experienced HIT-related thrombosis prior to initiation of DOAC therapy. Seven patients received parenteral therapy with argatroban prior to initiation of DOAC treatment. Nine patients were treated with apixaban while three received rivaroxaban for an average of 9.33 days while hospitalized. Zero patients experienced the primary outcome of HIT-related thrombosis, and no patients experienced major bleeding post DOAC initiation. All patients achieved platelet recovery while receiving DOAC therapy. CONCLUSIONS: In this small retrospective study of adult patients treated for acute HIT, treatment with DOAC therapy was not associated with in-hospital thrombotic or hemorrhagic events.
Authors: Matej Samoš; Tomáš Bolek; Ingrid Škorňová; Jakub Benko; Ján Staško; Peter Kubisz; Peter Galajda; Marián Mokán Journal: J Thromb Thrombolysis Date: 2019-11 Impact factor: 2.300
Authors: Rossella Marcucci; Martina Berteotti; Anna M Gori; Betti Giusti; Angela A Rogolino; Elena Sticchi; Agatina Alessandrello Liotta; Walter Ageno; Erica De Candia; Paolo Gresele; Marina Marchetti; Marco Marietta; Armando Tripodi Journal: Blood Transfus Date: 2020-12-28 Impact factor: 3.443
Authors: Austin A Robinson; Cory R Trankle; Grayson Eubanks; Christopher Schumann; Paul Thompson; Ryan L Wallace; Shouri Gottiparthi; Benjamin Ruth; Christopher M Kramer; Michael Salerno; Kenneth C Bilchick; Cody Deen; Michael C Kontos; John Dent Journal: JAMA Cardiol Date: 2020-06-01 Impact factor: 14.676